Objectives. In this article we describe the long-term follow-up of patients with carcinoma in situ (CIS) of the urinary bladder and examine whether the extent of CIS, the presence of associated papillary tumors, or the response to treatment influence the course of the disease.
Conclusions. CIS of the bladder is a malignancy with a poor prognosis, especially in patients not responding after intravesical treatment. Early detection and adjuvant in travesical treatment after TUR of concomitant papillary tumors are required. In patients not responding after intravesical treatment, radical surgery is necessary before pro gression occurs. The number of biopsies positive for CIS, not the presence of concomi tant superficial tumors, was an indicator for progression or recurrence.
Carcinoma in situ (CIS) of the urinary bladder was first described by Melicow.1 At cystoscopy, the urothelium may appear normal or may be red, granular, mossy, or pink. Therefore, the endo scopic diagnosis of CIS at an early stage may be difficult. Several investigators have reported that urinary cytology is a more reliable way to detect CIS and may give an indication of the extent and grade of the disease.2 Sensitive examinations Submitted: September 19,1994, accepted: October 14,1994 to detect CIS are karyometry3 and flow cytometry of bladder washings. 4 The most commonly affected sites are the trigone or floor of the bladder, in cluding the periurethral areas and the bladder neck. The posterior and lateral walls are also fre quently involved but in situ carcinoma is seldom found on the anterior wall or dome. Multiple sites of involvement are frequent.5 CIS potentially in volves the whole urothelium. Moreover, CIS of the urinary bladder morphometrically looks like an invasive bladder carcinoma6 and has the potential to progress into invasive bladder carcinoma. The percentage of patients with CIS who develop an invasive cancer is 50% to 83%.2,7'10 The time to progress from in situ to invasive carcinoma has been reported to be 18 to 77 months.11 Prognos tic factors for progression are multicentricity and extent of mucosal involvement.5 The predictive value for progression in patients with CIS associ ated with papillary disease is less clear. These pa tients with CIS associated with Stage Ta or T1 tu mors have a more varied course than those with CIS alone. Occasionally, transurethral resection with fulguration of adjacent urothelium will pro vide long-term control of focal CIS associated with early stage transitional cell carcinoma. More com monly, however, the disease is diffuse and associ ated with a higher risk of progression.5 CIS is classified as primary when it is not asso ciated with any previous or present history of pap illary tumor, as concomitant when it is present to gether with a papillary superficial tumor, and as secondary when it occurs during the follow-up of a papillary tumor.
The objective of this report was to determine whether the extent of CIS, the presence of con comitant papillary tumors, or treatment response influence the course of the disease.
MATERIAL AND METHODS
In this report, we describe 52 patients with pri mary CIS or CIS associated with pTa or pTl tu mors among a group of 469 patients with super ficial bladder carcinoma treated in a randomized prospective study.12 Analysis was performed for all 52 patients and of subgroups of patients. Sub groups were identified by the extent of CIS, the presence or absence of papillary tumors, and the response to intravesical treatment.
Biopsies of suspect areas as well as random biop sies were taken, and complete transurethral resec tion (TUR) of all visible associated papillary tu mors was performed. The presence of CIS was confirmed by a referee pathologist. None of the patients was previously treated for CIS. Patients were randomized to one of three treatment groups. In group I, mitomycin (Mutamycin, Kyowa, Christiaens) 30 mg in 50-mL saline was given once a week for 4 weeks and thereafter once a month for 5 months. Intravesical immunotherapy was done using bacille Calmette-Guerin (BCG)-RIVM (group II, the Dutch strain, Lundbeck) or BCG-Tice (group III, Oncotice, Organon Teknika). BCG (5 X 108 bacilli in 50-mL of saline) was given once a week for 6 consecutive weeks. Instillations were started between 7 and 15 days after diagno sis of CIS. After completion of the instillation therapy, patients were followed every 3 months by urine cytology, cystoscopy, and eventually biopsy. Tumor recurrence was histologically proven by biopsy. If t}ie urine cytology was positive with neg ative findings at cystoscopy, random biopsies were taken. In case of a first recurrent tumor or CIS at 3 or 6 months in BCG-treated patients, a second 6-week course of BCG was given. In mitomycintreated patients, three additional monthly instilla tions were given in case of a first recurrence at 6 months. In case of a first recurrence at or after 9 months and in case of progression, the patient went off study and was followed for survival. Pro gression was defined as muscle-invasive bladder cancer, involvement of prostatic tissue, or the de velopment of métastasés. Complete response was defined as negative cystoscopy, negative cytology, and negative biopsy, which means there was no CIS or a papillary tumor in the resected tissue.
Statistical analysis was performed using Stu dent' s t test and chi-square test for numerical and categorical data, respectively.
RESULTS

Of the 52 patients with CIS, 29 had primary CIS and 23 had concomitant superficial tumors (pTa in 11 and pTl in 12 patients). Fifteen patients (29%)
received mitomycin, 15 (29%) received BCG-RIVM, and 22 (42%) received BCG-Tice. Of the 52 pa tients, 34 (65%) showed a complete response after TUR and intravesical treatment. Of the 34 respon ders, 19 (56%) remained free of disease, with a mean follow-up of 45 months (range, 11 to 81). Re currence of a superficial papillary tumor or CIS was seen in 8 of 34 patients (24%): 2 patients had re current CIS, 6 patients developed a superficial pap illary tumor without CIS (3 had pTa tumors, 3 had pTl tumors). Of these 6 patients, 3 previously also had a papillary tumor associated with the CIS. The median time to recurrence was 31 months (95% confidential interval [Cl], 9 to 53 months). Pro gressive disease (PD) in responders occurred in 6 patients (18%) after a median duration of 29 months (95% Cl, 11 to 70 months). Two patients had lymph node métastasés, of whom 1 also had lung métas tasés. In 3 patients with progression, a cystectomy was performed. In 1 of these patients, the resected specimen also showed CIS in one ureter.
Of the 18 patients (35%) who had no response after one or two treatment courses, 6 (33%) had persistent CIS without progression into invasive bladder cancer, and 12 (67%) nonresponders showed PD after a mean time of 14 months (95% Cl, 6 to 28 months). Of the 6 patients with 582 UROLOGY® / April 1995 / Volume 45, Numiuir 4 persistent CIS, 3 underwent a cystectomy. In one resected specimen CIS was histologically con firmed in both ureters and in the prostatic urethra. One patient had CIS in the prostatic tissue and right ureter. Two patients were treated with one or more courses of intravesical BCG; in 1 patient this was followed by monthly instillations of epirubicin for more than 2 years. One patient was not treated further. Disease-related death was not seen in these 6 patients.
In the 12 nonresponders who showed progres sion, treatment was as follows: 5 underwent a rad ical cystectomy; 3 were treated with external ra diotherapy; 1 patient had positive lymph nodes at laparotomy and died within 6 months, disease re lated; 1 patient with lymph node métastasés was treated with chemotherapy: methotrexate, vin blastine, doxorubicin, and cisplatin (MVAC), fol lowed by external irradiation; and 2 patients were not treated because of a poor clinical condition and because of the probability of liver métastasés. Of the 5 patients who were operated on, 2 were free of disease with a follow-up of 3.5 and 4 years and 3 developed métastasés later, of which 2 re ceived treatment with MVAC and 1 patient died of a disease-related condition after the cystectomy.
Of the 12 patients with PD, 5 died of a diseaserelated condition.
In the total group, 18 of 52 (35%) patients showed PD after a median duration of 19 months (95% Cl, 6 to 70 months). Eleven of 52 patients (21%) underwent a radical cystectomy. During the follow-up period, 16 patients died: 7 (13%) deaths were disease related, 5 among the nonre sponders. Follow-up of the whole group and treat ment groups is summarized in Table I. There were no significant differences in response rate, progression rate, or time to progression be tween the BCG-RIVM-and BCG-Tice-treated patients. When comparing the mitomycin-treated patients with the BCG-treated patients, we could not find any significant differences (Table I) .
With regard to the extent of CIS, comparison of patients with one or two small positive biopsy results versus three or more positive biopsy results of CIS showed no significant differences in response rate, progression rate, or time to progression (Table II) . Also, the recurrence rate and progression rate of the patients with primary CIS versus CIS associated with PTa tumors versus CIS associated with PT1 tumors were not significantly different (Table III) . Significant differences could only be found when comparing treatment responders to nonresponders (Table IV) . The number of patients who developed PD and who underwent radical cystectomy was significantly higher in the nonresponders (P = 0.0012 and 0.008, respectively).
COMMENT
Early detection of CIS of the bladder has been considerably improved by cytologic examination of the urine and multiple biopsies of normal-and abnormal-looking bladder mucosa. The clinical management, however, remains a problem, since uncertain biologic behavior of CIS provides no firm basis for categorical treatment recommenda tions. In most instances nowadays, clinicians ini tiate intravesical immunotherapy or chemother
apy with the aim to eradicate CIS, to prevent the development of muscle-invasive bladder cancer, and to prevent or delay cystectomy. In patients who achieved a complete remission with intra vesical therapy, the cystectomy rate was signifi cantly lower and the time to cystectomy longer compared with the nonresponders.10 Long-term benefit of intravesical chemotherapy and im munotherapy for carcinoma in situ has also been reported.13 '14 In our report we examined several prognostic factors. The extent of CIS had no prognostic sig nificance in our series. With regard to the absence or presence of concomitant papillary tumors, it is assumed that concomitant CIS behaves more fa vorably than primary CIS because it is detected and treated earlier. 15 On the other hand, concomi tant high-grade pTl tumors might contribute more to PD than the CIS component does, even when a complete TUR had taken place.16'17 Our analysis of patients with primary CIS versus patients with concomitant CIS with either pTa tumors or pTl tumors showed no difference in treatment response and course of the disease. Significant differences could only be found between responders and non responders, detrimental to the nonresponders, which will indicate a very intensive follow-up and often more aggressive treatment. Other reports confirm our experience with patients who failed the registered treatment. Their clinical behavior differs significantly, with a higher progression and cystectomy rate, a shorter time to cystectomy, and a higher disease-related death rate.10'15'18'19
When we compare the results of this report with the prognosis of patients with papillary tumors alone, we conclude that CIS of the bladder has a more malignant behavior than high-risk papillary tumors; the percentage of PD in our report is 35% in patients with CIS versus 18% in 62 patients with pTl grade 3 tumors without CIS treated in the same protocol12 (unpublished data after 5 years of follow-up). In the literature, the percent age of PD in high-grade, high-stage tumors is 20% to 30%.16 Although the percentage of complete re sponse in this, as in other studies, is high (60% to 89%),5,20,21 CIS still remains a highly malignant disease with the potential to involve the whole urothelium and to develop into PD.
It is important to realize that histologic criteria of CIS were not clearly defined in the past. Today, consensus has been achieved that only grade 3 CIS should be called CIS and all other atypical cellular patterns of the epithelial cells should be inter preted as atypia (or dysplasia).22 Furthermore, studied patient groups with CIS are often very small, as in this report. The results mentioned herein explain why patients with CIS require ad juvant treatment with intravesical chemotherapy or immunotherapy and why early detection, early treatment, and careful follow-up are necessary.
CONCLUSION
CIS of the bladder is known as a malignancy with a poor prognosis and a high risk to develop into invasive bladder cancer. This report confirms the poor prognosis, especially in nonresponding patients. Early radical cystectomy should be con sidered in nonresponding patients to avoid further progression into muscle invasive disease and metastases. In this study, the treatment regimen, the extent of CIS, and the presence of papillary tu mors did not influence the course of the disease. 
EDITORAL COMMENT
The unpredictability of carcinoma in situ (CIS) is a clini cally important dilemma. This review of 52 patients with CIS is derived from an original series of 469 patients previously considered to be at relatively low risk of disease recurrence. The observed 11% incidence of CIS is similar to that re ported in the United States.1 This study clearly confirms that even with effective intravesical treatment, CIS carries a poor prognosis. With an average follow-up of 45 months, disease progression occurred in 35% of patients and disease-related death in 13%. Most patients (65%) had complete response to intravesical therapy, but even with complete response, 18% subsequently progressed and 6% died of the disease. This 6% mortality is equal to that reported for early cystectomy in pa tients with CIS. Nonresponders fared significantly worse, with 67% of patients having disease progression and 28% of patients dying of disease despite the frequent use of cystec tomy. These data clearly show that residual CIS after intra vesical therapy is an ominous prognostic sign and supports the recommendation for cystectomy.
The timing of cystectomy is critical, and in this study av eraged 19 months in both the responder and nonresponder subgroups. The earliest cystectomy was done 10 months fol lowing initiation, of intravesical therapy. Although delay in cystectomy may preclude surgical cure, we can also make the mistake of removing bladders prematurely. With bacille Cal mette-Guérin (BCG) immunotherapy, several investigators have found that patients with residual CIS at 3 months of fol low-up can have complete response by 6 months. Southwest Oncology Group investigators have demonstrated that three additional BCG instillations given at 3 months significantly increase the complete response rate at 6 months. Based on these data, I recommend postponing cystectomy until 6 months unless patients have evidence of increasing disease. With residual disease at 6 months, however, timely cystec tomy or alternate therapy is essential.
